Breaking News

Financial Report: ICON

April 30, 2014

Revenues up 10% in the quarter

ICON
 
1Q Revenues: $350 million (+10%)
 
1Q Earnings: $36.2 million (+63%)
 
Comments: Gross business wins were $494 million in the quarter, representing a gross book to bill of 1.41. Net business wins were $427 million, representing a net book to bill of 1.22. Income from operations, excluding restructuring and other items, was $43.0 million or 12% of revenue. In the quarter the company agreed to acquire Aptiv Solutions, a provider of adaptive and medical device trials, for $143.5 million in cash.

blog comments powered by Disqus
  • Cryogenic Cold Chain Risk Mitigation

    Cryogenic Cold Chain Risk Mitigation

    Kristin Brooks, Contract Pharma||November 13, 2015
    Mark Sawicki of Cryoport explains the requirements, challenges, and regulatory aspects around cryogenic logistics

  • A Biologic Innovator

    A Biologic Innovator's Pursuit to Uphold Patents

    Kristin Brooks, Contract Pharma||October 12, 2015
    Amgen v. Sandoz biosimilars litigation could impact the industry for years to come

  • 2015 Contracting & Outsourcing Wrap-up

    2015 Contracting & Outsourcing Wrap-up

    Kristin Brooks, Contract Pharma||September 30, 2015
    A huge success, with another year of record attendance, sold-out exhibit hall, and a great line up of informative sessions

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Bringing Transparency and Collaboration to CRO Oversight

    Bringing Transparency and Collaboration to CRO Oversight

    Craig Morgan , goBalto Inc. ||November 17, 2015
    Relationships between sponsors and CROs are getting stronger

  • Getting Real

    Michael Pollock, PPD||November 17, 2015
    Partnering for clinical and real-world evidence studies